These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

865 related items for PubMed ID: 11682510

  • 1. Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation.
    Solano C, Muñoz I, Gutiérrez A, Farga A, Prósper F, García-Conde J, Navarro D, Gimeno C.
    J Clin Microbiol; 2001 Nov; 39(11):3938-41. PubMed ID: 11682510
    [Abstract] [Full Text] [Related]

  • 2. Analysis of cytomegalovirus (CMV) viremia using the pp65 antigenemia assay, the amplicor CMV test, and a semi-quantitative polymerase chain reaction test after allogeneic marrow transplantation.
    Ksouri H, Eljed H, Greco A, Lakhal A, Torjman L, Abdelkefi A, Ben Othmen T, Ladeb S, Slim A, Zouari B, Abdeladhim A, Ben Hassen A.
    Transpl Infect Dis; 2007 Mar; 9(1):16-21. PubMed ID: 17313466
    [Abstract] [Full Text] [Related]

  • 3. A prospective study comparing quantitative Cytomegalovirus (CMV) polymerase chain reaction in plasma and pp65 antigenemia assay in monitoring patients after allogeneic stem cell transplantation.
    Gentile G, Picardi A, Capobianchi A, Spagnoli A, Cudillo L, Dentamaro T, Tendas A, Cupelli L, Ciotti M, Volpi A, Amadori S, Martino P, de Fabritiis P.
    BMC Infect Dis; 2006 Nov 21; 6():167. PubMed ID: 17118205
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Diagnosing cytomegalovirus disease in CMV seropositive renal allograft recipients: a comparison between the detection of CMV DNAemia by polymerase chain reaction and antigenemia by CMV pp65 assay.
    Lo CY, Ho KN, Yuen KY, Lui SL, Li FK, Chan TM, Lo WK, Cheng IK.
    Clin Transplant; 1997 Aug 21; 11(4):286-93. PubMed ID: 9267717
    [Abstract] [Full Text] [Related]

  • 6. CMV monitoring after peripheral blood stem cell and bone marrow transplantation by pp65 antigen and quantitative PCR.
    Schulenburg A, Watkins-Riedel T, Greinix HT, Rabitsch W, Loidolt H, Keil F, Mitterbauer M, Kalhs P.
    Bone Marrow Transplant; 2001 Oct 21; 28(8):765-8. PubMed ID: 11781628
    [Abstract] [Full Text] [Related]

  • 7. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction.
    Yakushiji K, Gondo H, Kamezaki K, Shigematsu K, Hayashi S, Kuroiwa M, Taniguchi S, Ohno Y, Takase K, Numata A, Aoki K, Kato K, Nagafuji K, Shimoda K, Okamura T, Kinukawa N, Kasuga N, Sata M, Harada M.
    Bone Marrow Transplant; 2002 Apr 21; 29(7):599-606. PubMed ID: 11979310
    [Abstract] [Full Text] [Related]

  • 8. Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real-world review.
    Tan BH, Chlebicka NL, Low JG, Chong TY, Chan KP, Goh YT.
    Transpl Infect Dis; 2008 Oct 21; 10(5):325-32. PubMed ID: 18627578
    [Abstract] [Full Text] [Related]

  • 9. Monitoring of CMV infection: a comparison of PCR from whole blood, plasma-PCR, pp65-antigenemia and virus culture in patients after bone marrow transplantation.
    Hebart H, Müller C, Löffler J, Jahn G, Einsele H.
    Bone Marrow Transplant; 1996 May 21; 17(5):861-8. PubMed ID: 8733710
    [Abstract] [Full Text] [Related]

  • 10. Comparison of antigenemia assay and semiquantitative polymerase chain reaction test for monitoring active cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.
    Pajand O, Ziyaeyan M, Mousavi S, Fatolahzadeh B, Hojabri Z, Bahador A, Abdossamadi Z.
    Exp Clin Transplant; 2008 Jun 21; 6(2):149-54. PubMed ID: 18816243
    [Abstract] [Full Text] [Related]

  • 11. Comparison of two quantitative CMV PCR tests, Cobas Amplicor CMV Monitor and TaqMan assay, and pp65-antigenemia assay in the determination of viral loads from peripheral blood of organ transplant patients.
    Piiparinen H, Höckerstedt K, Grönhagen-Riska C, Lautenschlager I.
    J Clin Virol; 2004 Jul 21; 30(3):258-66. PubMed ID: 15135746
    [Abstract] [Full Text] [Related]

  • 12. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F, Alberú J, Soto-Ramírez LE, González-Aguirre H, Muñoz Trejo T, Mancilla E, Díliz H, Correa-Rotter R, Sierra-Madero J.
    Rev Invest Clin; 2002 Jul 21; 54(3):198-203. PubMed ID: 12183888
    [Abstract] [Full Text] [Related]

  • 13. Relationship of cytomegalovirus load assessed by real-time PCR to pp65 antigenemia in organ transplant recipients.
    Sanghavi SK, Abu-Elmagd K, Keightley MC, St George K, Lewandowski K, Boes SS, Bullotta A, Dare R, Lassak M, Husain S, Kwak EJ, Paterson DL, Rinaldo CR.
    J Clin Virol; 2008 Aug 21; 42(4):335-42. PubMed ID: 18495527
    [Abstract] [Full Text] [Related]

  • 14. Comparison of two commercially available pp65 antigenemia tests and COBAS Amplicor CMV Monitor for early detection and quantification of episodes of human CMV-viremia in transplant recipients.
    May G, Kuhn JE, Eing BR.
    Intervirology; 2006 Aug 21; 49(5):261-5. PubMed ID: 16714854
    [Abstract] [Full Text] [Related]

  • 15. CMV antigenemia (the lower matrix protein PP65), a marker for the guidance of antiviral therapy in cytomegalovirus disease after orthotopic heart transplantation.
    Iberer F, Tscheliessnigg KH, Halwachs G, Auer T, Wasler A, Petutschnigg B, Müller H, Freigassner M, Allmayr T, Hipmair G.
    Wien Klin Wochenschr; 1995 Aug 21; 107(23):718-22. PubMed ID: 8560893
    [Abstract] [Full Text] [Related]

  • 16. [Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients].
    Torre-Cisneros J, Caston-Osorio JJ, Martín C, Rivero A, Doblas A, Rojas R, Gómez P, Martínez F, Torres A.
    Enferm Infecc Microbiol Clin; 2010 Jan 21; 28(1):6-12. PubMed ID: 19409666
    [Abstract] [Full Text] [Related]

  • 17. Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy or human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients.
    Lilleri D, Baldanti F, Gatti M, Rovida F, Dossena L, De Grazia S, Torsellini M, Gerna G.
    J Med Virol; 2004 Jul 21; 73(3):412-8. PubMed ID: 15170637
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of the NucliSens CMV pp67 assay for detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantation.
    Hebart H, Rudolph T, Loeffler J, Middeldorp J, Ljubicic T, Jahn G, Einsele H.
    Bone Marrow Transplant; 2002 Aug 21; 30(3):181-7. PubMed ID: 12189537
    [Abstract] [Full Text] [Related]

  • 19. Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients.
    Gimeno C, Solano C, Latorre JC, Hernández-Boluda JC, Clari MA, Remigia MJ, Furió S, Calabuig M, Tormo N, Navarro D.
    J Clin Microbiol; 2008 Oct 21; 46(10):3311-8. PubMed ID: 18753357
    [Abstract] [Full Text] [Related]

  • 20. [Evaluation of cytomegalovirus quantification in blood by the R-gene real-time PCR test].
    Marque-Juillet S, Touzard A, Monnier S, Fernand-Laurent C, Therby A, Rigaudeau S, Harzic M.
    Pathol Biol (Paris); 2010 Apr 21; 58(2):162-5. PubMed ID: 19854587
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.